Risk factors in the progression of subclinical atherosclerosis in women with systemic lupus erythematosus

Arthritis Care and Research

Volumn 66, Issue 8, 2014, Pages 1177-1185

  Lertratanakul, Apinya ^a,b   Wu, Peggy ^a,b   Dyer, Alan R ^a,b   Kondos, George ^c   Edmundowicz, Daniel ^d   Carr, James ^a,b   Ramsey Goldman, Rosalind ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; HYDROXYCHLOROQUINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AORTA CALCIUM; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY CALCIUM SCORE; DISEASE ACTIVITY; DISEASE COURSE; ELECTRON BEAM TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MULTIDETECTOR COMPUTED TOMOGRAPHY; RISK ASSESSMENT; SLEDAI; SUBCLINICAL ATHEROSCLEROSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ATHEROSCLEROSIS; CAROTID INTIMA-MEDIA THICKNESS; DISEASE PROGRESSION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RISK FACTORS;

EID: 84904978964     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22271     Document Type: Article

References (31)

1. Ward MM,. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 338-46.
2. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-7.
3. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR, et al. Radiology plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) Study 1. Radiology 2005; 234: 35-43.
4. Yiu KH, Wang S, Mok MY, Ooi GC, Khong PL, Mak KF, et al. Pattern of arterial calcification in patients with systemic lupus erythematosus. J Rheumatol 2009; 36: 2212-7.
5. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407-15.
6. Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, Sammaritano L, et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 3412-9.
7. Thompson T, Sutton-Tyrrell K, Wildman RP, Kao A, Fitzgerald SG, Shook B, et al. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 2008; 58: 835-42.
8. Rua-Figueroa I, Arencibia-Mireles O, Elvira M, Erausquin C, Ojeda S, Francisco F, et al. Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study. Ann Rheum Dis 2010; 69: 1136-9.
9. Kiani AN, Post WS, Magder LS, Petri M,. Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Rheumatology (Oxford) 2011; 50: 2071-9.
10. Wu PW, Rhew EY, Dyer AR, Dunlop DD, Langman CB, Price H, et al. 25-hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1387-95.
11. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
12. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
13. Gladman DD, Ibanez D, Urowitz MB,. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002; 29: 288-91.
14. Detrano RC, Anderson M, Nelson J, Wong ND, Carr JJ, McNitt-Gray M, et al. Coronary calcium measurements: effect of CT scanner type and calcium measure on rescan reproducibility. MESA Study. Radiology 2005; 236: 477-84.
15. Budoff MJ, McClelland RL, Nasir K, Greenland P, Kronmal RA, Kondos GT, et al. Cardiovascular events with absent or minimal coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 2009; 158: 554-61.
16. Berry JD, Liu K, Folsom AR, Lewis CE, Carr JJ, Polak JF, et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in Young Adults Study and Multi-Ethnic Study of Atherosclerosis. Circulation 2009; 119: 382-9.
17. Von Feldt JM, Scalzi LV, Cucchiara AJ, Morthala S, Kealey C, Flagg SD, et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2220-7.
18. Rasouli ML, Nasir K, Blumenthal RS, Park R, Aziz DC, Budoff MJ,. Plasma homocysteine predicts progression of atherosclerosis. Atherosclerosis 2005; 181: 159-65.
19. Li J, Chai S, Tang C, Du J,. Homocysteine potentiates calcification of cultured rat aortic smooth muscle cells. Life Sci 2003; 74: 451-61.
20. Van Campenhout A, Moran CS, Parr A, Clancy P, Rush C, Jakubowski H, et al. Role of homocysteine in aortic calcification and osteogenic cell differentiation. Atherosclerosis 2009; 202: 557-66.
21. Sari RA, Polat MF, Taysi S, Bakan E, Capoglu I,. Serum lipoprotein(a) level and its clinical significance in patients with systemic lupus erythematosus. Clin Rheumatol 2002; 21: 520-4.
22. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG,. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008; 117: 176-84.
23. Guerra R, Yu Z, Marcovina S, Peshock R, Cohen JC, Hobbs HH,. Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study. Circulation 2005; 111: 1471-9.
24. Magder LS, Petri M,. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012; 176: 708-19.
25. Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S,. Vascular stiffness in women with systemic lupus erythematosus. Hypertension 2001; 37: 1075-82.
26. De Leeuw K, Freire B, Smita J, Bootsma H, Kallenberg CG, Bijl M,. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 2006; 15: 675-82.
27. Petri M, Kiani A, Post W, Christopher-Stine L, Magder LS,. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011; 70: 760-5.
28. Karim R, Hodis HN, Detrano R, Liu CR, Liu CH, Mack WJ,. Relation of Framingham risk score to subclinical atherosclerosis evaluated across three arterial sites. Am J Cardiol 2008; 102: 825-30.
29. Adler Y, Fisman EZ, Shemesh J, Schwammenthal E, Tanne D, Batavraham IR, et al. Spiral computed tomography evidence of close correlation between coronary and thoracic aorta calcifications. Atherosclerosis 2004; 176: 133-8.
30. Kathiresan S, Larson MG, Keyes MJ, Polak JF, Wolf P, D'Agostino RB, et al. Assessment by cardiovascular magnetic resonance, electron beam computed tomography, and carotid ultrasonography of the distribution of subclinical atherosclerosis across Framingham risk strata. Am J Cardiol 2007; 99: 310-4.
31. Karp I, Abrahamowicz M, Fortin PR, Pilote L, Neville C, Pineau CA, et al. Longitudinal evolution of risk of coronary heart disease in systemic lupus erythematosus. J Rheumatol 2012; 39: 968-73.